Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9790809 | 0.84 | LMNA (0.67) | CYP1A2CYP3A4CYP2C19HPGDKMT2A | |
| SCHEMBL10331371 | 0.83 | CYP2C19 (0.44) | CYP1A2CYP3A4CYP2C19HPGDKMT2A | |
| SCHEMBL8989516 | 0.83 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C19HPGDKMT2A | |
| SCHEMBL14051590 | 0.82 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C19HPGDKMT2A | |
| SCHEMBL14032969 | 0.82 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C19HPGDKMT2A | |
| SCHEMBL11360493 | 0.82 | SMN1; SMN2 (0.71) | CYP1A2CYP3A4CYP2C19HPGDKMT2A | |
| SCHEMBL6971568 | 0.81 | CYP1A2 (0.54) | CYP1A2CYP3A4CYP2C19HPGDKMT2A | |
| SCHEMBL3368984 | 0.81 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C19HPGDKMT2A | |
| SCHEMBL16771241 | 0.81 | CYP1A2 (0.54) | CYP1A2CYP3A4CYP2C19HPGDKMT2A | |
| SCHEMBL8427120 | 0.81 | KMT2A (0.47) | CYP1A2CYP3A4CYP2C19HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107722148-B | Solid polyaluminoxane composition, catalyst for olefin polymerization, and method for producing olefin polymer | 三井化学株式会社 | 2021-06-08 | — | — | CN | disclosed |
| CN-107722146-B | Method for producing solid polyaluminoxane composition | 三井化学株式会社 | 2021-02-26 | — | — | CN | disclosed |
| US-10870715-B2 | Solid polyaluminoxane composition, olefin polymerization catalyst, olefin polymer production method and solid polyaluminoxane composition production method | MITSUI CHEMICALS, INC. (JP) | 2020-12-22 | — | — | US | disclosed |
| EP-3312200-B1 | SOLID POLYALUMINOXANE COMPOSITION, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMER PRODUCTION METHOD AND SOLID POLYALUMINOXANE COMPOSITION PRODUCTION METHOD | MITSUI CHEMICALS INC (JP) | 2019-06-19 | — | — | EP | disclosed |
| US-10150823-B2 | Solid polyaluminoxane composition, olefin polymerization catalyst, olefin polymer production method and solid polyaluminoxane composition production method | MITSUI CHEMICALS, INC. (JP) | 2018-12-11 | — | — | US | disclosed |
| EP-3312200-A1 | SOLID POLYALUMINOXANE COMPOSITION, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMER PRODUCTION METHOD AND SOLID POLYALUMINOXANE COMPOSITION PRODUCTION METHOD | Mitsui Chemicals, Inc. (JP) | 2018-04-25 | — | — | EP | disclosed |
| EP-2955187-B1 | SOLID POLYALUMINOXANE COMPOSITION, CATALYST FOR OLEFIN POLYMERIZATION AND METHOD FOR PRODUCING OLEFIN POLYMER | MITSUI CHEMICALS INC (JP) | 2018-01-31 | — | — | EP | disclosed |
| US-20170240664-A1 | SOLID POLYALUMINOXANE COMPOSITION, OLEFIN POLYMERIZATION CATALYST, OLEFIN POLYMER PRODUCTION METHOD AND SOLID POLYALUMINOXANE COMPOSITION PRODUCTION METHOD | MITSUI CHEMICALS, INC. (JP) | 2017-08-24 | — | — | US | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9676879-B2 | Solid polyaluminoxane composition, olefin polymerization catalyst, olefin polymer production method and solid polyaluminoxane composition production method | MITSUI CHEMICALS, INC. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-7820817-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100105693-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105693-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105693-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-29 | — | — | US | disclosed |
| US-7439366-B2 | Phenacylamine derivatives, process for their production and pesticides containing them | ISHIHARA SANGYO KAISHA LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| US-7439366-B2 | Phenacylamine derivatives, process for their production and pesticides containing them | ISHIHARA SANGYO KAISHA LTD. (JP) | 2008-10-21 | — | — | US | disclosed |
| EP-1753429-A1 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060019962-A1 | substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-26 | — | — | US | disclosed |
| WO-2005117883-A1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005117883-A1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105693-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | CYP1A2 1308/4885CYP3A4 1733/4885CYP2C19 2400/4885 |
| US-20060019962-A1 | substituted piperazine compounds that are useful modulators of muscarinic receptors; 1-(5-bicyclo[2.2.1]hept-2-enylmethyl)-4-(3-nitro-2-pyridyl)-piperazine; treatment of COPD, asthma, urinary incontinence, glaucoma, Alzheimer's (AchE inhibitors), and pain | ACHE, CHRM5, CHRM3 | CYP1A2 273/4885CYP3A4 694/4885CYP2C19 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.